Cargando…

Patients avec cancers thoraciques et COVID-19 : au cœur de la tempête: Patients with chest cancer and COVID-19: at the heart of the storm

A meta-analysis of the Chinese studies in April 2020, including 3600 patients with cancer and COVID-19, first reported an increase of the COVID-19 risk and the case-fatality in these patients. Then, North-American and European series confirmed the increased COVID-19 risk for patients with cancer, as...

Descripción completa

Detalles Bibliográficos
Autores principales: Gounant, V., Brosseau, S., Soussi, G., Pluvy, J., Guezzour, N., Vauchier, C., Brouk, Z., Namour, C., Zalcman, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SPLF. Publié par Elsevier Masson SAS. Tous droits réservés. Published by Elsevier Masson SAS 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504965/
https://www.ncbi.nlm.nih.gov/pubmed/34659597
http://dx.doi.org/10.1016/S1877-1203(21)00121-X
Descripción
Sumario:A meta-analysis of the Chinese studies in April 2020, including 3600 patients with cancer and COVID-19, first reported an increase of the COVID-19 risk and the case-fatality in these patients. Then, North-American and European series confirmed the increased COVID-19 risk for patients with cancer, as the increased risk of severe COVID-19 and death, when compared with general population, adjusting for age. Patients with lung cancer have the highest risk of severe respiratory forms, and the highest risk of SARS-CoV2-induced death (25 to 30%), after patients with hematological cancers. Metastatic patients, with poor PS, and those having received a cytotoxic chemotherapy within the weeks preceding SARSCoV2 infection, are those with the highest risk of death. Conversely, being treated with immune checkpoint inhibitors would not favor the cytokine storm, which makes the severity of COVID-19. SARS-CoV2 pandemic, beyond having needed the generalization of drastic social distancing measures in hospitals, also needed organizational changes, to allow healthcare continuity for cancer patients. Adaptation of therapeutic protocols was needed, with increased intervals between cycles, the choice of less toxic protocols, the systematic use of hematological growth factors, and teleconsultations follow-up. Lastly, mRNA-based SARS-CoV2 vaccines are efficient in patients with thoracic cancer, provided the interval of 21/28 days between the two injections is maintained, since protective immunization seems delayed, especially after cytotoxic chemotherapy. Only 13% of patients with very low protective antibodies titers would need a third booster injection, with a clear rise in protective antibodies titers induced by such a third injection. © 2021 SPLF. Published by Elsevier Masson SAS. All rights reserved.